En iedere keer is het weer kassa voor de farmaceuten, die wel geïnteresseerd zijn in stoppen met maar niet in opgeven van roken.
Het is juist de nicotine-ontwenningsmiddelen industrie die veel van het anti-roken onderzoek financiert. Zo wordt bijvoorbeeld meer dan 70% van het Tobacco Free Initiative van de Wereld Gezondheidsorganisatie gesponsord door Farmacia (Nicorette) en GlaxoKline (Zyban). We zijn dus benieuwd wie dit onderzoek betaald heeft.
| “Within the [North American] region, central nervous system products, currently growing at 18 percent constitute the largest class, with a value of $14.5 billion. The growth leaders in this class currently are anti-epilepsy and anti-smoking products.” IMS Health Drug Monitor, Oct. 2, 1998. | “In 1996, sales of nicotine medications increased by 11% over average sales during the 4-week national GASO [the American Cancer Society’s Great American Smokeout] promotion; sales during the specific week of GASO increased 30%.” “Impact of Promotion of the Great American Smokeout and Availability of Over-the-Counter Nicotine Medications, 1996,” Centers for Disease Control, MMWR, Sept. 19, 1997. | For the ad industry, the [smoking-cessation] products have become one of the biggest growth engines: Ad spending for smoking-cessation aids jumped to $220 million last year [1996] from $13 million the year before, according to Interpublic Group’s McCann-Erickson.” “Tobacco deal heats up nicotine-patch war: Settlement includes money for treatment of smoking habit; marketers looking for windfall,” The Wall St. Journal, July 5, 1997. |
